W1P3 Flashcards
Viruses
- type
- replication process
Viruses are obligate intracellular parasites
Viral replication depends primarily on synthetic processes of the host cell
Antiviral agents must ideally inhibit virus-specific events:
Block viral entry into the cell
Block viral exit from the cell
Be active inside the host cell
Exert some sort of immunomodulatory effect
What are the viral events that antivirals need to target
Antiviral agents must ideally inhibit virus-specific events:
Block viral entry into the cell
Block viral exit from the cell
Be active inside the host cell
Exert some sort of immunomodulatory effect
How is an antiviral’s therapeutic effect measured?
Since viruses are not “alive”, drugs cannot “kill” them
A therapeutic agent’s antiviral effect is measured by its ability to inhibit viral replication:
- 50% Inhibitory Concentration (IC50). should have half as many virally infected cells compared to when we started after giving antiviral
Steps of Viral Replication
- Attachment
- Entry
- Uncoating
- Synthesis
a. Early proteins
b. Nucleic acids
c. Late proteins - Assembly
- Release
Who are the people in Canada who are at high risk of influenza- related complications and thus should be vaccinated
Adults aged > 65 years; residents of nursing homes or long-term care facilities
All children aged <5 years, especially 6 to 23 months
children above 6 months should get vaccinated
Canada approved antivirals for Influenza
Oseltamivir (PO)
Zanamivir (inhalation)
Peramivir (IV) [Not marketed in Canada]
Baloxavir Marboxil (PO)
Oseltamivir (PO)
Oral capsule, liquid suspension
Aged >14 d
Generic version available
Antivirals for Influenza
Zanamivir (inhalation)
Powder for oral inhalation through a plastic device
Aged ≥7 y
Not recommended in patients with airway diseases (eg asthma, COPD)
Antivirals for Influenza
Peramivir (IV)
Given intravenously
Aged ≥2 y
appoved for use but Not marketed in Canada
Antivirals for Influenza
Baloxavir Marboxil (PO)
Oral tablets (1 dose) Aged ≥12 y (FDA approval pending for patients aged 1-11 y) - for non severe cases
Antivirals for Influenza
What are all circulaing influenze viruses RESISTANT to?
Adamantanes
Adamantanes
M2 ion inhibitors for influenza virus that has become useless because of resistance
Point mutation of the M2 protein lead to resistance
Resistance emerges rapidly during treatment
- 30% of adults and 80% of children treated with amantadine will excrete resistant virus
- Persistant or recurrent fever in children who develop amantadine-resistant strains on treatment
Viral replication, transmission and virulence are not impaired by these mutations
Neuraminidase Inhibitor
Neuroaminidase is a receptor/ active site*
NA^ inhibitors: Cleave the bond between HA (on virus) and sialic acid receptor on host epithelial cells which is otherwise used to attach the virus to host
Neuraminidase inhibitor = cleaves the bond stated above ^ = clumping of viral particles = shutting down replication
Resistance to oseltamivir does not necessarily confer resistance to zanamivir
Mutations in the receptor affect the conformational change of the oseltamivir = antibiotic resistance
But this doesn’t affect zanamivir: mutations that prevent this conformational change prevent binding of oseltamivir (Panel B). Zanamivir and sialic acid still bind to NA active site despite H274Y mutation
Polymerase Inhibitors: Mechanism of Action1
polymerase inhibitors: inhibit ENDONUCLEASE activity
Benefits of Oseltamivir therapy
REDUCTION of
- Duration of illness in adults and children
0. 5 to1.5 days or 25-32% - Viral shedding and viral load
- need for Antibiotics
- length of hospializations
- hospital mortality
- however you need to be treated EARLY. It peaks at day 2*
Who do you treat with Oseltamivir
- During periods of community circulation of influenza viruses
Prompt empiric treatment is recommended for persons with suspected or confirmed influenza and:
- Respiratory illness requiring hospitalization
- Outpatients with progressive, severe, or complicated illness
- Outpatients at higher risk for influenza complications (i.e. pneumonia)
- Outpatients without risk factors but presenting early (<48 h) on a case-by-case basis
Prophylaxis of influenza contacts?
Prophylaxis (HALF THE DOSE of oseltamivir/zanamivir) of household contacts
- Reduces transmission
- Previously recommended for high-risk contacts
Early treatment of contacts may now be preferred
- NOT GOOD if they are already infected, because then if you give them half dose; you’re exposing the virus to subtherapeutic environment which PROMOTES resistance
Take home points for Infuenza
- treatment
- Window to treat?
- Resistance characteristic in influenza?
Antivirals are beneficial in treatment of influenza
Early treatment (<48 hrs) increases benefits - Severe disease, immunocompromised may still benefit from late treatment (up to 5 days)
Influenza has the ability to change rapidly
Next year’s circulating strains and their resistance profiles will determine best treatment strategies
Physicians need to stay up to date
http://www.phac-aspc.gc.ca/fluwatch/index-eng.php
Herpes Simplex Virus
These are enveloped, double stranded DNA viruses
Uses the Lytic cycle to transcribe viral DNA by the host cell and form new viral proteins
They can also travel up sensory neurons to start the LATENT cycle
stay FOR LIFE.
Commonly asymptomatic.
Symptoms include skin and mucous membrane lesions:
HSV1: Infections above the waist (mouth and tongue)
HSV2: infection below the waist (genitals)
* however there is a lot of cross over.
Herpes lesions in the mouth look like….
Cluster of small, painful, fluid-filled blisters
- They ooze and ulcerate
- Heal in a few weeks
Herpes has dormant stages and reactivation stages, it comes and goes.
reactivation is often asymptomatic BUT when it is,
you’ll see handful of blisters at the vermillion border (lip) on ONE side of the face
- these blisters a small and typically heal in a week
Acyclovir active against…
Active against:
HSV
VZV, varicella (lower affinity, thus requires higher doses)
Very poor activity against other herpesviruses
15-30% bioavailability p.o. (poor, need IV)
Acyclovir mechanism of action
Triphosphate form inhibits viral DNA synthesis by:
1) competing with dGTP for viral DNA polymerase
2) chain termination
Acyclovir - Resistance
in HSV and VZV
HSV Most often due to virus DEFICIENCY in TK [thymidine kinase, the target for this drug] Rarely due to altered TK or DNA pol Rare in immunocompetent 4-17% of isolates in immunocompromised
VZV
Mostly ALTERED TK (lower affinity for ACV)
Acylovir- clinical indications
- PO
- Topical
- IV
PO Genital herpes - Primary infection - Suppression of recurrences Oro-labial herpes - Primary - Recurrence Primary VZV
Topical
Keratoconjunctivitis
IV
- HSV encephalitis
- Neonatal HSV
- HSV in immunocompromised
- VZV (primary or reactivation) in immunocompromised
- Prophylaxis post bone marrow transplant
Acyclovir Side Effects
Well-tolerated
Neutropenia with prolonged courses
Nephrotoxicity when given IV
Neurotoxicity in renal failure
Valacyclovir
Pro-drug of acyclovir
Only p.o.
70% bioavailability** better bioavailability :)
Otherwise similar profile to acyclovir
Penciclovir / Famciclovir
Famciclovir is the prodrug of penciclovir and is available p.o. Guanosine analog 70% bioavailability Well-tolerated Same mechanism of action as acyclovir
Resistance:
- Able to overcome some resistance to acyclovir, but TK deficient mutants remain resistant
- Rare in immunocompetent
CMV- Cytomegalovirus
- which populations are at high risk of contracting this
usually you already have CMV and its just dormant
it gets activated in:
transplant patients who take immunosuppressants, creating an environment for CMV to reactivate
- so pts after allogenic HCT are at HIGH risk
in order of highest to least risk for allogenic HCT CMV R+ GVHD CMV R+ without GVHD CMV R- with GVHD CMV R- without GVHD
R+ means they’ve had CMV, R- i think means they haven’t prior too
AKA patient with GVHD are at higher risk
Define: Therapeutic Empirical Prophylactic Preemptive
Therapeutic: treat an established, clinical disease
Empirical: treat a possible disease, given signs or symptoms
Prophylactic: treat ALL members of a population to prevent the occurrence of clinical disease
Preemptive: treat individuals at high risk for clinical disease given laboratory markers
i.e. CMV and transplant patients* can’t be given prophylatically because of fatal side effects, they need to be MONITORED and carefully treated
Gancyclovir
Used to treat CMV
Guanosine analog
In vitro activity against all herpesviruses
100x more active against CMV than ACV
In CMV infected cells, the virally-encoded UL97 phosphotransferase performs first phosphorylation
After di and tri phoshorylation (cellular enzymes), GCV inhibits viral DNA pol
Should be given i.v., via central venous line
Gancyclovir RESISTANCE
CMV most often develops resistance by mutations in the UL97 gene (viral protein kinase) DNA pol (UL54) mutations are rare However, confer cross-resistance to cidofovir and foscarnet Double mutants (UL97 and UL54) are the most resistant ↑ duration of therapy ↑ chance of developing resistance
Gancyclovir clinical indications
CMV retinitis
- Treatment and suppression
- Can also be given intraocularly
CMV pneumonitis
- In combo with anti-CMV immunoglobulin
Prophylactic or pre-emptive
- Bone marrow transplant (Donnor-/Recipient+) -pre-emptive
- Solid organ transplant (D+/R-) ->prophylactically
Congenital CMV
Gancyclovir- Side Effects
Requires central line
Bone marrow toxicity
- Neutropenia (40%)
- Thrombocytopenia (15-20%)
Valgancyclovir
Oral pro-drug of gancyclovir
60% bioavailability
Indications:
- Treat & suppress CMV retinitis
- CMV prophylaxis in solid organ transplant
What you need to know about Cidofovir
- why is it second line and not first
Cytidine analog
In vitro activity against herpesviruses, papillomaviruses, polyomaviruses, adenoviruses
Does NOT depend on VIRAL ENZYMES for phosphorylation
good because resistance is RARE however it is SECOND line agent becuase it has DOSE dependant NEPHROTOXICITY
Cidofovir
- clinical indications
- Side effects
Clinical indications
CMV disease in
- immunosuppressed patients who do not tolerate GCV and foscarnet
- whose virus is suspected to be resistant to GCV and foscarnet
Side effects
- Dose-dependant nephrotoxicity
- Neutropenia
- Potentially carcinogenic and teratogenic
Foscarnet
- analog of?
- active against?
- Resistance
- how is it administered?
- dose must be adjusted in patients with?
Pyrophosphate analog
Active against all herpesviruses
[Does not require any phosphorylation
Directly inhibits DNA pol]
Active against CMV resistant to GCV (UL97) and TK deficient HSV / VZV
CMV resistance is rare
DNA pol mutation, after prolonged or repeated exposure
Must be given i.v.
Adjust in renal failure
First line for CMV vs second line treatments
First line:
Gancyclovir
Valgancyclovir
second line:
cidofovir
Foscarnet
Letermovir
- when it is administered? (therapeutic, prophylaxis, preemptive, empirically)
We don’t prophylaxis CMV with gancyclovir (cause its marrow toxic) but we do for letermovir (different mech of action and doenst have same toxicitiy)
Approved for prophylaxis of CMV infection in adult CMV-seropositive allogeneic HSCT
DOUBT you need to know the mechanism but here it is:
CMV replication involves cleaving of concatemeric genomic DNA and packaging of each genome into preformed virus capsids
The CMV terminase complex (UL51, UL56, UL89) performs these sequential events, a viral process not present in uninfected human cells
Letermovir inhibits the terminase complex by binding to UL56, UL51
Anti Hepatitis agents
Interferon- (HBV & HCV)
Ribavirin (HCV)
Nucleoside / nucleotide analogues (HBV)
Interferon a
- what is it
- how does it work
- how it is administered (po? iv? im?)
Large glycoproteins
Cytokines that possess antiviral, immunomodulatory and antiproliferative effects
No direct antiviral effect, but antiviral activity occurs via activation of host cells to produce a series of antiviral proteins
Intramuscular or subcutaneous injection
Attachment of large, inert polyethylene glycol (PEG) molecules enables once-weekly dosing
Interferon a
- side effects
- clinical indications
Side-effects: Flu-like syndrome Myelosuppression Neurotoxicity Autoimmune disorders (thyroiditis) Cardiovascular effects
Clinical indications
Chronic HBV
Acute and chronic HCV
Refractory codylomata accuminata (intralesional)
* NOT USED REALLY… Don’t focus too much on this
Ribavirin
Purine nucleoside analog, inhibits wide range of RNA and DNA viruses (broad spectrum— however really only works well for HEPATITIS)
Resistance very rare
HEPATITIS treatments
Interferon A
Ribavirin
Nucleoside / nucleotide inhibitors in chronic hepatitis B infection
Treatment of Hep C
Direct acting antiviral therapy available
TAKE HOME points on Antivirals
Antiviral agents have unique mechanisms of activity
- Can only inhibit replication- only NEW ones, so those that have already replicated and triggered proinflammatory response are out of reach
Resistance tends to emerge in the context of active replication in the face of antiviral treatment (subtherapeutic)*
What are some diagnostic methods you learned about?
Microscopy Culture Bacterial identification - biochemical tests, - identification systems Susceptibility testing Serology Nucleic acid-based detection
Acid- fast stain
- What does it work on
- why is it used vs gram stain?
Stain with carbolfuschin (red) and heat
Decolorize with acid alcohol
Counterstain with methylene blue
Used for Mycobacteria sp. Some bacteria (Nocardia sp., Actinomyces sp.) are “partially acid-fast” (when a lower concentration of acid is used)
Cell wall lipids/waxy layer do not allow these organisms to stain well on gram stain.
The cell wall lipids of the Mycobacterium do not dissolve when the acid alcohol is applied so the red stain doesn’t wash off
Which bacteria cannot be gram stained?
Intracellular organisms (chlamydia),
those that lack a cell wall (mycoplasma),
those that have a lot of cell wall lipids (mycobacteria), those that are too small to be seen on light microscopy (spirochetes)
What are the 5 types of Cultures?
- General purpose: capable of detecting most aerobic and facultatively anaerobic organisms
- Sheep’s blood agar - Enriched: supplemented with nutrients to promote the growth of more fastidious organisms
- Chocolate agar
3. Selective: supports growth of one type or group of microbes while inhibiting the growth of others MacConkey agar (for enterobacteriacea)
- Differential: allows grouping of microbes based on different characteristics demonstrated on the medium
- Sheep’s Blood Agar, MacConkey agar - Specialized: developed with additives for the purpose of isolating a specific pathogen
Sheeps Agar
Type of DIFFERENTIAL culture
Sheeps blood: the ability of the bacteria to hemolyze RBC helps you differentiate them
Alpha= partial hemolysis- so a greenish colour
Beta = complete hemolysis- clears the red, so it’s yellow area that is clear
Gamma = nothing hemolyzed – faint, mostly red
What are the different environments that need to be included in a culture
- Provide an example of which organism each environment is well suited for
After plating of specimen onto selected agars, these must be incubated
a. Aerobic environment
b. Microaerophilic environment – Campylobacter sp
c. CO2 rich environment – Streptococcus sp.
d. Anaerobic environment – Clostridium sp.
Blood culture
- difference in the two bottles
- what do the bottles contain
-
One bottle for aerobic recovery and another for anaerobic recovery
Bottle contains:
- Liquid media that is nutritionally enriched
- Antibiotic removal device or resin
- Anticoagulant
It is incubated at 35C for 5 days in a continuous-monitoring blood culture system
How do we detect growth in blood cultures
Growth is detected based on how much CO2 is produced
Continuous-monitoring systems
- Microbial growth and metabolism causes release of CO2
This can be detected in several ways:
- Using a pH sensitive membrane at the bottom of the bottle that changes color as CO2 is produced – alters the amount of light reflected
- Using a gas-permeable sensor at the bottom of the bottle that increases fluorescence output as CO2 is produced.
Catalase tests
- what is it used to differentiate
If bacteria produces catalase enzyme, it will break down H2O2 and bubble will appear
i.e. Staph are catalase positive
Strep are catalase NEG that’s how we differentiate between these two GRAM POSITIVE bacteria :)
Oxidase
- used on which type of bacteria
often used for gram neg. to see if it produces cytochrome oxidase, if it DOES it’ll turn purple/blue
Which test helps to differentiate between staph aureus and staph epidermis?
These are both Gram POSITIVE bacteria
use Coagulase test
aureus: coagulase positive
epidermis: coagulase neg
Motility Medium
- What is a type of bacteria this can help differentiate
You grow the bacteria in a line
if you only get a single dark line then you know the bacteria is NOT motile vs if the whole tube turns red, then you know the bacteria IS motile
Motility via flagella is common in the gram negative bacilli (enterobacteriaceae) – growth is indicated by the presence of red color
Triple Sugar Iron Agar
Used for gram Neg
Has three different types of sugars in it
Colour changes dictate what sugars ur bacteria is fermenting to help identify them